NASDAQ:QNRX - Nasdaq - US74907L3006 - ADR - Currency: USD
5.67
+0.19 (+3.49%)
The current stock price of QNRX is 5.67 USD. In the past month the price decreased by -46%. In the past year, price decreased by -74.59%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 16.81 | 301.01B | ||
AMGN | AMGEN INC | 13.81 | 147.14B | ||
GILD | GILEAD SCIENCES INC | 22.63 | 130.06B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1646.62 | 122.76B | ||
REGN | REGENERON PHARMACEUTICALS | 12.3 | 61.38B | ||
ARGX | ARGENX SE - ADR | 320.27 | 36.37B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 30.28B | ||
ONC | BEIGENE LTD-ADR | N/A | 24.70B | ||
BNTX | BIONTECH SE-ADR | N/A | 24.47B | ||
NTRA | NATERA INC | N/A | 19.23B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.60B | ||
BIIB | BIOGEN INC | 7.07 | 17.05B |
Quoin Pharmaceuticals Ltd. engages in the development of therapeutic products for the treatment of rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.
QUOIN PHARMACEUTICALS LT-ADR
23 Hata'as Street
Kfar Saba IL
CEO: Shai Yarkoni
Employees: 4
Company Website: https://quoinpharma.com/
Investor Relations: https://investors.quoinpharma.com/
Phone: 97299741444
The current stock price of QNRX is 5.67 USD. The price increased by 3.49% in the last trading session.
The exchange symbol of QUOIN PHARMACEUTICALS LT-ADR is QNRX and it is listed on the Nasdaq exchange.
QNRX stock is listed on the Nasdaq exchange.
QUOIN PHARMACEUTICALS LT-ADR (QNRX) has a market capitalization of 116.72M USD. This makes QNRX a Micro Cap stock.
QUOIN PHARMACEUTICALS LT-ADR (QNRX) currently has 4 employees.
QUOIN PHARMACEUTICALS LT-ADR (QNRX) has a resistance level at 6.01. Check the full technical report for a detailed analysis of QNRX support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
QNRX does not pay a dividend.
QUOIN PHARMACEUTICALS LT-ADR (QNRX) will report earnings on 2025-05-07.
QUOIN PHARMACEUTICALS LT-ADR (QNRX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-30.2).
The outstanding short interest for QUOIN PHARMACEUTICALS LT-ADR (QNRX) is 39.35% of its float. Check the ownership tab for more information on the QNRX short interest.
ChartMill assigns a fundamental rating of 2 / 10 to QNRX. QNRX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months QNRX reported a non-GAAP Earnings per Share(EPS) of -30.2. The EPS decreased by -194.92% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -57.05% | ||
ROE | -97.37% | ||
Debt/Equity | 0.32 |
ChartMill assigns a Buy % Consensus number of 83% to QNRX. The Buy consensus is the average rating of analysts ratings from 8 analysts.